BOSTON, April 16 (Reuters) - Women whose breast cancer may have spread survive a bit longer with weekly infusions of the drug Taxol than less-frequent treatments or treatment with a similar drug, ...
Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188) Patients with clinical stage I-IIIA ...
The objective response rate was 27.6% for arm 1 and 19.2% for arm 2. Median time to progression (TTP) was 18.4 and median survival (MS) was 38.6 weeks for arm 1. For arm 2, the median TTP and MS were ...
Please provide your email address to receive an email when new articles are posted on . A de-escalated, 12-week neoadjuvant treatment regimen of dual HER2 blockade with pertuzumab and trastuzumab plus ...
CAMBRIDGE, MA - July 23, 2013 - Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback